Daily Archives: January 24, 2022
European CDC on Omicron: “among Omicron cases reported to TESSy, 1.14% were hospitalised, 0.16% required ICU admission/respiratory support, and 0.06% died”.
24 Jan, 2022 | 08:54h | UTC
Case-control study: 3 doses of mRNA vaccines were associated with reduced infections with SARS-CoV-2 Omicron and Delta variants compared to no vaccination or 2 doses.
24 Jan, 2022 | 08:56h | UTCCommentaries: New data show booster doses protect against Omicron – CIDRAP
Related CDC Studies:
Commentary on Twitter
Study suggests receipt of 3 doses of mRNA #COVID19 vaccine, vs 2 doses or being unvaccinated, was associated with protection against both the Omicron and Delta variants; higher odds ratios for Omicron suggest less protection for Omicron than for Delta. https://t.co/kOZh0fq5TL
— JAMA (@JAMA_current) January 21, 2022
WHO updated roadmap for prioritizing uses of COVID-19 vaccines.
24 Jan, 2022 | 08:49h | UTCWHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines – World Health Organization
Commentary: WHO: COVID boosters should start with most vulnerable – Associated Press
Commentary on Twitter (thread – click for more)
UPDATED: The Strategic Advisory Group of Experts (SAGE) have revised the Roadmap for Prioritising Uses of #COVID19 vaccines.
? https://t.co/FJFlMpBSSK pic.twitter.com/4SNH7ZpSwz
— World Health Organization (WHO) (@WHO) January 21, 2022
WHO advisers weigh in on COVID-19 boosters, Pfizer vaccine in younger kids.
24 Jan, 2022 | 08:35h | UTCWHO advisers weigh in on COVID-19 boosters, Pfizer vaccine in younger kids – CIDRAP
Updated Guideline: Recommended drugs and biologics in adult patients with COVID-19.
24 Jan, 2022 | 08:52h | UTC
Commentary on Twitter (thread – click for more)
?JUST RELEASED: New clinical guidelines for COVID now including #Paxlovid (nirmatrelvir/ritonavir).
A ? on why Paxlovid is NOT first-line.https://t.co/h0puYpiFOK
— Andrew Morris (@ASPphysician) January 22, 2022
WHO Technical Brief: Enhancing response to Omicron SARS-CoV-2 variant.
24 Jan, 2022 | 08:36h | UTCEnhancing response to Omicron SARS-CoV-2 variant – World Health Organization
A guide to immunotherapy for COVID-19.
24 Jan, 2022 | 08:29h | UTCA guide to immunotherapy for COVID-19 – Nature Medicine
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.
24 Jan, 2022 | 08:28h | UTCA blood atlas of COVID-19 defines hallmarks of disease severity and specificity – Cell
Commentary on Twitter:
A simple?one-page summary of everything you need to know about Covid hallmarks of severity in the blood, how it differs from flu, sepsis, and much morehttps://t.co/s81Qb2SXmu @CellCellPress @KnightGenetics
(actually quite a rich resource @UniofOxford) pic.twitter.com/bk0AxwLItn— Eric Topol (@EricTopol) January 22, 2022
No amount of alcohol is good for the heart, says World Heart Federation.
24 Jan, 2022 | 08:23h | UTCNews Release: No amount of alcohol is good for the heart, says World Heart Federation
Commentary: No amount of alcohol is good for the heart, new report says, but critics disagree on science – CNN
Flying in the COVID-19 era: Science-based risk assessments and mitigation strategies on the ground and in the air.
24 Jan, 2022 | 08:32h | UTCFlying in the COVID-19 Era: Science-based Risk Assessments and Mitigation Strategies on the Ground and in the Air – National Academies of Sciences, Engineering, and Medicine (free registration required)
SARS-CoV-2 breakthrough infections elicit potent, broad and durable neutralizing antibody responses.
24 Jan, 2022 | 08:26h | UTCNews Release: Breakthrough infections spur strong antibody responses – University of Washington School of Medicine
Evidence-based clinical practice guidelines for functional dyspepsia.
24 Jan, 2022 | 08:19h | UTCRelated:
Dyspepsia: A stepwise approach to evaluation and management.
UEG Consensus on Functional Dyspepsia.
AHA Statement: Oral penicillin, not injectable, advised for people with high-risk rheumatic heart disease.
24 Jan, 2022 | 08:21h | UTCNews Release: Oral penicillin, not injectable, advised for people with high-risk rheumatic heart disease – American Heart Association
The WSES/SICG/ACOI/SICUT/AcEMC/SIFIPAC guidelines for diagnosis and treatment of acute left colonic diverticulitis in the elderly.
24 Jan, 2022 | 08:24h | UTCRelated:
ACP Guideline: Diagnosis and management of acute left-sided colonic diverticulitis.
Review: Changing paradigms in the management of acute uncomplicated diverticulitis.
Review: Elective surgical management of diverticulitis
State of the Art Review | Management of colonic diverticulitis
Drains, germs, or steel: Multidisciplinary management of acute colonic diverticulitis
Systematic review: Management of colonic diverticulitis
WSES Guidelines for the Management of Acute Colonic Diverticulitis
ASCRS Guidelines for the Treatment of Left-Sided Colonic Diverticulitis
RCT: In children with peanut allergy, initiation of peanut oral immunotherapy before age 4 years induced desensitization in 71% of patients and remission in 21%.
24 Jan, 2022 | 08:18h | UTCEfficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study – The Lancet (link to abstract – $ for full-text)
News Release: Oral immunotherapy induces remission of peanut allergy in some young children – NIH News Releases
Commentary: Peanut Oral Immunotherapy at Younger Age Ups Desensitization in Children – HealthDay
RCT: Lactic acid gel vs. metronidazole for recurrent bacterial vaginosis in women aged 16 years and over.
24 Jan, 2022 | 08:13h | UTC
Review: Artificial intelligence in health and medicine.
24 Jan, 2022 | 08:16h | UTCAI in health and medicine – Nature Medicine (if the link is paywalled, try this one)
Related: High-Performance Medicine: The Convergence of Human and Artificial Intelligence
Commentary on Twitter (thread – click for more)
? Our review of #AI for medicine, just published @NatureMedicine https://t.co/OAoAGmErns@pranavrajpurkar, Emma Chen, Oishi Banerjee pic.twitter.com/oufp3nnOob
— Eric Topol (@EricTopol) January 20, 2022
Perspective: Preventing digital overdiagnosis.
24 Jan, 2022 | 08:14h | UTCPreventing Digital Overdiagnosis – JAMA (free for a limited period)
Related: Overdiagnosis: it’s official – the term is now included in the medical subject headings (MeSH) vocabulary. (several articles on the subject)
Review: Health literacy interventions for secondary prevention of coronary artery disease.
24 Jan, 2022 | 08:12h | UTC
Review: Cardiovascular computed tomography imaging for coronary artery disease risk: plaque, flow and fat.
24 Jan, 2022 | 08:09h | UTC
Outcome of patients with an ultralow-risk 70-gene signature in the MINDACT trial.
24 Jan, 2022 | 08:08h | UTCOutcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Related:
Commentary on Twitter:
In MINDACT, 15% of the pts (n=1000) had an ultra-low 70-gene signature. Although some had tumors >2 cm (20%) & were LN+ (20%), prognosis was outstanding
8-year DMFI 97%
8-year BCSS 99.6%Most of these patients received adj treatment. Did they need it?https://t.co/V9SH2StuQE
— Paolo Tarantino (@PTarantinoMD) January 22, 2022
Retrospective cohort study: Occurrence and predictors of pericardial effusion requiring invasive treatment following heart valve surgery.
24 Jan, 2022 | 08:10h | UTC
M-A: Impact of enhanced recovery protocols after pancreatoduodenectomy.
24 Jan, 2022 | 08:00h | UTCImpact of enhanced recovery protocols after pancreatoduodenectomy: meta-analysis – British Journal of Surgery (link to abstract – $ for full-text)
Related:
See also: Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines (some guidelines are free)
Commentary on Twitter
Do you apply @ErasSociety protocols ?♀️after pancreatoduodenectomy ?!
? Meta analysis on > 3000 cases
⬇️ ERAS decreases overall morbidity, DGE, hospital stay, readmission rate
? ERAS should be implemented, but in ALL patients?! https://t.co/fSmPYdof57 pic.twitter.com/L02q7bkLWU
— Giovanni Marchegiani (@Gio_Marchegiani) January 22, 2022
RCT: The addition of trastuzumab to neoadjuvant chemoradiotherapy for HER2-overexpressing esophageal cancer did not improve outcomes.
24 Jan, 2022 | 08:04h | UTCTrastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
In a phase III trial in 203 pts with HER2+ oesophageal cancer, adding trastuzumab to neoadjuvant CRT did not significantly improve mDFS (19.6 vs 14.2 months; HR 0.99; P = 0.97). The incidence of grade 3 and 4 TRAEs was 43% & 21% vs 54% & 22%: https://t.co/wx0NmVMyCR #esocsm
— NatureRevClinOncol (@NatRevClinOncol) January 21, 2022
KDOQI US commentary on the 2021 KDIGO Guideline for the management of blood pressure in chronic kidney disease.
24 Jan, 2022 | 07:56h | UTCRelated:
Commentary on Twitter
The @nkf KDOQI work group agreed with most of the @goKDIGO BP recommendations while highlighting the weak evidence base especially for patients with diabetes and advanced CKD ca. 2022 #Nephpearls
?? https://t.co/X40N0pacY6 https://t.co/HEHlSD06yO pic.twitter.com/Rpil8m0QOn
— Edgar V. Lerma ?? (@edgarvlermamd) January 21, 2022